LifeStance Health Group

LFST · NASDAQ

$12.22+$0.45 (+3.82%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $11.77

LFST analyst rating

BuyConsensus of 9 analysts over the last 12 months. 78% rate it a buy.

Strong buy0
Buy7
Hold2
Underperform0
Sell0

12-month price target · 13 analysts

Average $13.87 (+13.5% upside)

Low: $7.07
Now: $12.22
High: $18.90

Upgrades and downgrades

The latest rating actions, newest first

LFST analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Keybanc	Oct 5, 2026	Maintains	Overweight	$13.00 → $15.00	50%
Barclays	Sep 10, 2026	Maintains	Overweight	$13.00 → $15.00	60%
Canaccord Genuity	Sep 9, 2026	Maintains	Buy	$13.00 → $15.00	43%
BTIG	Aug 19, 2026	Maintains	Buy	$16.00 → $18.00	46%
JP Morgan	Aug 14, 2026	Maintains	Neutral	$9.00 → $13.00	54%
BTIG	Aug 7, 2026	Maintains	Buy	$15.00 → $16.00	46%
BTIG	Jul 24, 2026	Maintains	Buy	$12.00 → $15.00	46%
Canaccord Genuity	Jul 21, 2026	Maintains	Buy	$11.00 → $13.00	43%
Barclays	Jul 14, 2026	Maintains	Overweight	$9.00 → $13.00	60%
Keybanc	Jul 13, 2026	Maintains	Overweight	$11.00 → $13.00	50%

The case for and against

Updated Oct 18, 2026

Bull case

LifeStance Health Gr is well positioned to compound growth because its core outpatient mental health platform sits in a fragmented market with strong demand, low single-digit market share, and ~600 centers that support efficient expansion through de novos and tuck-in deals. The bull case is further reinforced by clinician recruitment, ~2% CAC, stable payer relationships, and improving utilization and productivity, which helped drive 2Q revenue of $435.4M (+26% y/y), adjusted EBITDA of $66M (+94% y/y), and margin expansion to 15.2%. Specialty Care adds a higher-growth, higher-margin lever, with revenue modeled to rise from ~$70M in 2026 to ~$200M in 2030 and center margins expanding from ~33% to ~42%, supported by TMS, Spravato, and future psychedelic therapies.

Bear case

LifeStance Health Gr is exposed to meaningful reimbursement, payer concentration, and clinician-retention risk, with UnitedHealthcare and Elevance Health representing 14% and 15% of FY25 revenue, respectively. Although its existing patient funnel and >1M patients reduce marketing intensity, growth still depends on successful clinician recruitment, specialty-care training, and utilization ramp-up, while any narrowing of networks or lower payor rates could pressure volumes and margins. Its brick-and-mortar model also carries elevated fixed costs versus virtual-only peers, and competition, policy uncertainty, and economic weakness could further restrain profitability and patient demand.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.